1. Home
  2.  |  
  3. CURRENT AFFAIRS
  4.  |  
  5. Corporate Current Affairs

Explained: Twitter loses protection under Section 79 of IT Act- What it means?

1 day ago
Twitter will no longer be protected under Section 79 of the IT Act and its top executives will now be liable for all the content on its platform that is considered inflammatory or considered unlawful in nature.

Bharat Biotech shares complete data of Covaxin research studies 

2 days ago
The studies conducted on Covaxin's Phase I trials aimed to assess the vaccine's safety, immune response and to determine right dosage.

NOVAVAX COVID-19 vaccine, to be produced by Serum Institute of India, shows 90% efficacy

3 days ago
NOVAVAX COVID-19 vaccine provides 100% protection against the moderate and severe symptoms of the disease and has shown 90.4 percent efficacy overall in phase 3 trials.

COVAXIN phase 3 trial data to be made public in July 2021

Jun 10, 2021
COVAXIN phase 3 trial data: As per the interim analysis of the Covaxin trials, the vaccine's overall efficacy is 78 percent against symptomatic disease and 100 percent against hospitalizations. 

COVID-19 vaccine: Serum Institute gets DCGI’s nod to manufacture Sputnik V vaccine in India

Jun 5, 2021
Serum Institute of India has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Russia for developing the Sputnik V vaccine at its licensed Hadapsar facility.

Privacy of users our highest priority, says WhatsApp in response to Centre's 'trick consent' statement

Jun 3, 2021
Whatsapp clarified that the recent update does not change the privacy of people's personal messages. The platform said that the purpose is to provide additional information about how people can interact with businesses if they choose to do so.

Centre books 30 cr doses of Biological-E's COVID-19 vaccine 

Jun 3, 2021
Biological-E's COVID-19 vaccine is an RBD protein subunit vaccine. It is currently undergoing Phase-3 clinical trials.

COVID-19 Vaccine: India’s DCGI waives post-approval bridging trials for Pfizer, Moderna

Jun 2, 2021
The Drug Controller General of India (DCGI) waives the requirement for foreign companies to conduct post-launch bridging trials here in the country. Read all you need to know.

Tata Steel’s T V Narendran becomes new president of CII

Jun 1, 2021
The Confederation of Indian Industry (CII) announced that it has elected T V Narendran, CEO and Managing Director of Tata Steel as its new President for 2021-22.

COVID-19: Zydus Cadila seeks DCGI approval for clinical trials for monoclonal antibody therapy

May 27, 2021
Zydus Cadila is the only Indian company that has been able to develop a neutralizing monoclonal antibody-based cocktail to neutralize COVID-19. Read what is monoclonal antibody therapy?

Pfizer COVID-19 vaccine suitable for all aged 12 and above: Pfizer tells Centre

May 27, 2021
The US pharmaceutical giant Pfizer plans to supply 50 million COVID-19 vaccines to India in 2021, with few conditions in place. Read all you need to know.

Moderna's COVID-19 vaccine 100 percent effective in 12-17 age group: Trial study

May 26, 2021
Moderna had conducted clinical trials on at least 3,732 participants aged between 12 and 17 years. No cases of COVID-19 were observed in any of the vaccinated participants and "no significant safety concerns" were identified, as per study results. 

WhatsApp files lawsuit against Indian government, says new media rules mean end to privacy

May 26, 2021
WhatsApp's lawsuit asks the Delhi High Court to declare that one of the centre's new rules as a violation of privacy rights in India's constitution, as it requires the social media companies to identify the "first originator of information" when authorities demand it.

Bharat Biotech confident of obtaining WHO's emergency use listing for Covaxin

May 25, 2021
Covaxin, developed by Bharat Biotech in collaboration with ICMR, has already received regulatory approval from 11 countries.

Sputnik V COVID-19 vaccine: India’s Panacea Biotec, RDIF to produce 100 million doses per year

May 25, 2021
In April 2021, Panacea and the RDIF had announced their plan to produce 100 million doses of the Sputnik V COVID-19 vaccine per year.

COVID-19 Vaccines in India: Know Which Coronavirus vaccines will be available in India and How do they Work | Explainer of the Day

May 25, 2021
COVID-19 Vaccines in India: With the Central Government announcing an ambitious plan of making available over 2 billion Coronavirus vaccines to the Indian citizens from August to December 2021, several new COVID-19 vaccines are likely to be introduced into the Indian Market. Let’s know all about the current and future COVID-19 vaccines that will be available in India and how do they work!

Microsoft to retire Internet Explorer in June 2022

May 25, 2021
Microsoft announced that the future of Internet Explorer on Windows 10 is in Microsoft Edge. What is Microsoft Edge?

COVID-19 vaccine: Bharat Biotech may begin trials of Covaxin on 2-18 years old from June

May 24, 2021
The clinical trials for the vaccine will take place in 525 subjects at different sites, including AIIMS, Patna, AIIMS, Delhi, and Meditrina Institute of Medical Sciences, Nagpur.

Gautam Adani overtakes China’s Zhong Shanshan to become 2nd richest Asian

May 21, 2021
Gautam Adani is now ranked behind Asia’s richest person, RIL Chairman Mukesh Ambani who is ranked 13th on the Bloomberg Billionaires Index with a net worth of $76.3B.

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

Get App